Very encouraging results, first-in-human 225Ac-DOTATATE Dosimetry Results from Part 1 of the ACTION-1 Trial, presented by Dr Gary Ulaner on behalf of Dr Michael Morris.

Current Issue: Alpha Before Beta: Exceptional Response to First-Line 225Ac-DOTATATE in a Patient of Metastatic Neuroendocrine Tumor With Extensive Skeletal Involvement dlvr.it/SgJd25

Happy about our recent publication on: Signaling Network Response to Alpha-Particle Targeted Therapy with Actinium-225 Labeled Minigastrin Analogue 225Ac-PP-F11N Reveals Radiosensitizing Potential of HDAC Inhibitors jnm.snmjournals.org/content/early/…

George is presenting his work on 225Ac/213Bi radionuclide generators!

Current Issue: Delayed Nephrotoxicity After 225Ac-PSMA-617 Radioligand Therapy dlvr.it/SnPb2n

☢️Radiopharma remains HOT
Missed out on Point and Rayze?
Check out Fusion Pharmaceuticals $FUSN
$FUSN already has a collaboration with $AZN

Pharma is interested E2E solutions:
assets + manufacturing + supply chain 👇

Upcoming catalysts:
FPI-2265 (225Ac-PSMA) mCRC Ph 2 data

Today, targeted #alpha therapy using #225Ac_ PSMA brought renewed hope for 6 late-stage #prostate cancer patients. Exciting clinical progress continues!
Special thanks to professor
Mike Sathekge for his wise counsel and support throughout.

Relative Efficacy of 225Ac-PSMA-617 and 177Lu-PSMA-617 in Prostate Cancer Based on Subcellular Dosimetry

You can see the free full text of the research by Hwan Lee

Link : cms.tsnmjournals.org/Uploads/Articl…

New in JNM: A novel ²²⁵Ac-DOTA-based pre-targeted radioimmunotherapy (PRIT) system has been shown to cure a highly lethal form of advanced intraperitoneal #OvarianCancer in a preclinical setting with minimal side effects. ow.ly/gw7B50PMVVt

#NuclearMedicine #RPTherapy

Current Issue: A New Radiopharmaceutical 225Ac-DOTA-IBA in the Treatment of a Case of Bone Metastases dlvr.it/T6ClZ2

When is right moment to RLT in prostate cancer?

☑️ should before castration be the way?
☑️ should before chemotherapy will be?
☑️ what about Alfa (225Ac) with higher LET (linear energy transfer) ?

PSMA conference - UCSF/UCLA/PCF/Urotoday Oliver Sartor Jeremie Calais Daniel Castellano

Epithelial #ovariancancer is the most lethal type, but a preclinical study has promising results. Targeting the HER2 protein with anti-HER2 225Ac-PRIT cured 83% of mice, while only 30% of mice treated with traditional methods survived. More from NBC Bay Area:

Actinium-225 PSMA RLT for metastatic prostate cancer in The Lancet Oncology

Conclusion spot on: 'future prospective studies investigating the safety and efficacy of 225Ac-PSMA RLT in patients who have not responded to 177Lu-PSMA RLT are needed.' sciencedirect.com/science/articl…

$FUSN: The only public Radiopharma company with in-house manufacturing capability for 225Ac
Also, at AACR (Apr 5th) Ph2 25-30 pts interim will be first company-sponsored 225Ac-PSMA data reveal
Below is the compilation of academia led trials for 225Ac-PSMA (image source: Leerink)

Alpha RLT will be the future of Theranostics?

☑️ More energy and less range
☑️ Challenges: adverse effects, access
☑️ Alpha (225Ac) + beta (177Lu) RLT cocktails ?

Matthias Eiber PSMA conference - UCSF/UCLA/PCF/Urotoday UroToday.com Jeremie Calais

What happens when we use a potent alpha emitter (225Ac) and a monoclonal antibody (J591) in #PSMA -TRT in castration-resistant prostate cancer? Led by Scott Tagawa, our new publication in @JCO describes safety & preliminary efficacy in dose escalation. A tweetorial! 1/9

Bayer initiates phase I study with novel targeted radionuclide therapy 225Ac─PSMA─Trillium in advanced metastatic prostate cancer
pharmabiz.com/NewsDetails.as…
Published by pharmabiz.com

The last #AACR24 New Drugs on the Horizon session kicks off with 225Ac-PSMA-Trillium (BAY 3563254) — a new targeted radiotherapy from Bayer. Unfortunately all slides were “Do Not Post” so no structure here. 😢

There is a presentation link on the last slide though

📢 Exciting Medical News! Blue Earth Therapeutics' 225Ac-rhPSMA-10.1 shows excellent potential for prostate cancer treatment with high PSMA binding, cellular internalization, and tumor suppression.

Learn More ➡️ bit.ly/3ZmgANW

#EANM23